{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:20:03Z","timestamp":1780374003894,"version":"3.54.1"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T00:00:00Z","timestamp":1674345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Endometrial cancer is becoming an increasing problem. Taking into account its pathomechanisms, we aimed to investigate whether FGF 21, an important metabolism regulator, could be used as a biomarker for endometrial cancer. The study included 233 patients who were classified into five subgroups depending on the result of the histological examination: endometrial carcinomas, sarcomas, endometrial polyps, fibroids, and normal endometrium. Statistically significantly higher FGF 21 levels were found in patients diagnosed with malignant lesions (p &lt; 0.001). FGF 21 concentration correlated with the degree of cellular differentiation (p = 0.020) and the presence of lymph node metastases (p = 0.009). The diagnostic performance characteristics of FGF 21 as an EC diagnostic marker demonstrated an AUC of 0.677. Of all of the assessed biomarkers, FGF 21 had the highest specificity (90%), yet limited sensitivity (41%). Additionally, HE4 and CA 125 were confirmed to have roles as EC biomarkers, with a higher accuracy for HE4 (79% vs. 72%).<\/jats:p>","DOI":"10.3390\/diagnostics13030399","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T03:26:41Z","timestamp":1674444401000},"page":"399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus"],"prefix":"10.3390","volume":"13","author":[{"given":"Anna","family":"Jagodzi\u0144ska","sequence":"first","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-204 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Chudecka-G\u0142az","sequence":"additional","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-204 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-681X","authenticated-orcid":false,"given":"Kaja","family":"Michalczyk","sequence":"additional","affiliation":[{"name":"Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, 70-204 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Pius-Sadowska","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University in Szczecin, al. Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Wieder-Huszla","sequence":"additional","affiliation":[{"name":"Department of Clinical Nursing, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1935-5285","authenticated-orcid":false,"given":"Anna","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Clinical Nursing, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Machali\u0144ski","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University in Szczecin, al. Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,22]]},"reference":[{"key":"ref_1","first-page":"199","article-title":"The Global Cancer Observatory\u2014All Cancers","volume":"419","author":"Ferlay","year":"2020","journal-title":"Int. Agency Res. Cancer-WHO"},{"key":"ref_2","unstructured":"Markowska, J., and M\u0105dry, R. (2018). Zarys Ginekologii Onkologicznej, Termedia Wydawnictwa Medyczne. Wydanie 3 uzup."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Michalczyk, K., Niklas, N., Rychlicka, M., and Cymbaluk-P\u0142oska, A. (2021). The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer. Diagnostics, 11.","DOI":"10.3390\/diagnostics11030494"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The Therapeutic Potential of FGF21 in Metabolic Diseases: From Bench to Clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-nutr-071816-064800","article-title":"Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis","volume":"38","author":"BonDurant","year":"2018","journal-title":"Annu. Rev. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1101\/gad.184788.111","article-title":"Endocrine Fibroblast Growth Factors 15\/19 and 21: From Feast to Famine","volume":"26","author":"Potthoff","year":"2012","journal-title":"Genes Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"655575","DOI":"10.3389\/fcvm.2021.655575","article-title":"The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases","volume":"8","author":"Yan","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","article-title":"Serum Concentrations and Tissue Expression of a Novel Endocrine Regulator Fibroblast Growth Factor-21 in Patients with Type 2 Diabetes and Obesity","volume":"71","author":"Mraz","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/EJE-10-0454","article-title":"Daily Physical Activity, Fasting Glucose, Uric Acid, and Body Mass Index Are Independent Factors Associated with Serum Fibroblast Growth Factor 21 Levels","volume":"163","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/postgradmedj-2018-136002","article-title":"Increased Serum\/Plasma Fibroblast Growth Factor 21 in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"95","author":"Wang","year":"2019","journal-title":"Postgrad. Med. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-2007-985148","article-title":"Circulating FGF-21 Levels in Normal Subjects and in Newly Diagnose Patients with Type 2 Diabetes Mellitus","volume":"116","author":"Chen","year":"2008","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates with Muscle and Hepatic Insulin Resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","article-title":"Increased Serum FGF21 Levels in Patients with Nonalcoholic Fatty Liver Disease","volume":"40","author":"Yilmaz","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast Growth Factor 21 Levels Are Increased in Nonalcoholic Fatty Liver Disease Patients and Are Correlated with Hepatic Triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","article-title":"Fibroblast Growth Factor-21 Improves Pancreatic \u03b2-Cell Function and Survival by Activation of Extracellular Signal-Regulated Kinase 1\/2 and Akt Signaling Pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Shenoy, V.K., Beaver, K.M., Fisher, F.M., Singhal, G., Dushay, J.R., Maratos-Flier, E., and Flier, S.N. (2016). Elevated Serum Fibroblast Growth Factor 21 in Humans with Acute Pancreatitis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164351"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Prida, E., \u00c1lvarez-Delgado, S., P\u00e9rez-Lois, R., Soto-Tielas, M., Estany-Gestal, A., Fern\u00f8, J., Seoane, L.M., Qui\u00f1ones, M., and Al-Massadi, O. (2022). Liver Brain Interactions: Focus on FGF21 a Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113318"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e8791","DOI":"10.15252\/emmm.201708791","article-title":"FGF21 Gene Therapy as Treatment for Obesity and Insulin Resistance","volume":"10","author":"Jimenez","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2020.11.026","article-title":"FGF21 in Obesity and Cancer: New Insights","volume":"499","author":"Lu","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated Genomic Characterization of Endometrial Carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1010428318757103","DOI":"10.1177\/1010428318757103","article-title":"HE4 Is Superior to CA125 in the Detection of Recurrent Disease in High-Risk Endometrial Cancer Patients","volume":"40","author":"Abbink","year":"2018","journal-title":"Tumor Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.5306\/wjco.v11.i6.378","article-title":"Preoperative Markers for the Prediction of High-Risk Features in Endometrial Cancer","volume":"11","author":"Panyavaranant","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.5603\/GP.a2018.0103","article-title":"The Preoperative Serum CA125 Can Predict the Lymph Node Metastasis in Endometrioid-Type Endometrial Cancer","volume":"89","author":"Comert","year":"2018","journal-title":"Ginekol. Pol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.3802\/jgo.2019.30.e70","article-title":"Improved Preoperative Risk Stratification with CA-125 in Low-Grade Endometrial Cancer: A Multicenter Prospective Cohort Study","volume":"30","author":"Reijnen","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/1533034616666644","article-title":"Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients with Endometrial Cancer","volume":"16","author":"Bian","year":"2017","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ijgo.13140","article-title":"HE4 Tumor Marker as a Predictive Factor for Lymphatic Metastasis in Endometrial Cancer","volume":"149","year":"2020","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Behrouzi, R., Barr, C.E., and Crosbie, E.J. (2021). HE4 as a Biomarker for Endometrial Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194764"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cymbaluk-P\u0142oska, A., Garguli\u0144ska, P., Chudecka-G\u0142az, A., Kwiatkowski, S., Pius-Sadowska, E., and Machali\u0144ski, B. (2020). The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients. Diagnostics, 10.","DOI":"10.3390\/diagnostics10060414"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial Cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fonc.2019.00744","article-title":"The Role of Metabolic Syndrome in Endometrial Cancer: A Review","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nrc3174","article-title":"Molecular Mechanisms of Cancer Development in Obesity","volume":"11","author":"Khandekar","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ebiom.2018.02.022","article-title":"Obesity and Cancer: Existing and New Hypotheses for a Causal Connection","volume":"30","author":"Stone","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jnci\/dji132","article-title":"Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk within the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"97","author":"Kaaks","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"789174","DOI":"10.1155\/2012\/789174","article-title":"Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms","volume":"2012","author":"Arcidiacono","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast Growth Factor 21 in Non-Alcoholic Fatty Liver Disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Adams, A.C., Coskun, T., Rovira, A.R., Schneider, M.A., Raches, D.W., Micanovic, R., Bina, H.A., Dunbar, J.D., and Kharitonenkov, A. (2012). Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038438"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1210\/en.2009-0221","article-title":"Fibroblast Growth Factor 21 Controls Glycemia via Regulation of Hepatic Glucose Flux and Insulin Sensitivity","volume":"150","author":"Berglund","year":"2009","journal-title":"Endocrinology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a Novel Metabolic Regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast Growth Factor 21 Corrects Obesity in Mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/3\/399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:13:11Z","timestamp":1760119991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/3\/399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,22]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["diagnostics13030399"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13030399","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,22]]}}}